SIBIONICS prezentuje GS3, najcieńsze na świecie CGM, na konferencji ATTD 2025
Shenzhen-based SIBIONICS made waves at the 2025 Advanced Technologies & Treatments for Diabetes (ATTD) conference in Amsterdam by unveiling GS3, the world’s thinnest continuous glucose monitoring (CGM) device. The revolutionary GS3 measures just 2.9mm thick – comparable to a small coin – and weighs only 1.5 grams, making it virtually unnoticeable when worn. Its ultra-compact design features three connection methods for smartphone compatibility and NFC-enabled pairing that establishes connectivity in just three seconds with a simple tap.
The GS3 represents a significant leap forward in glucose monitoring technology, integrating multiple AI capabilities to help users better understand their glucose data and manage their levels more effectively. The device offers direct connectivity with smartwatches and dedicated receivers, catering to diverse user needs – particularly benefiting children and elderly users who may prefer alternative display options. Continuous algorithm improvements enhance the system’s monitoring stability and accuracy, delivering more reliable glucose management solutions.
During ATTD 2025, SIBIONICS hosted a dedicated symposium where clinical experts presented research on CGM applications and analyzed variations in Ambulatory Glucose Profile (AGP) patterns across different patient populations. These findings contribute valuable insights to advance precision diabetes treatment approaches. The symposium also featured the debut of Continuous Ketone Monitoring (CKM) technology, with researchers sharing preliminary findings from studies investigating its potential for Type 1 diabetes management.
With the launch of GS3, SIBIONICS reinforces its leadership in CGM innovation, continuing its mission to develop lighter, more precise, and smarter glucose monitoring solutions for people with diabetes worldwide. The company’s commitment to technological advancement is supported by its team of over 500 employees, including more than 125 R&D scientists from top universities in China and the United States, all working to transform patient lives through cutting-edge biosensors, intelligent algorithms, and user-friendly software solutions.
